2026-06-14T03:55:10Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/189982025-04-29T09:47:27Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_19609col_20.500.12105_16968

00925njm 22002777a 4500 dc Antunes, Liliana author Mazagatos, Clara author Martínez-Baz, Iván author Gomez, Verónica author Borg, Maria-Louise author Petrović, Goranka author Duffy, Róisín author Dufrasne, François E author Dürrwald, Ralf author Lazar, Mihaela author Jancoriene, Ligita author Oroszi, Beatrix author Husa, Petr author Howard, Jennifer author Melo, Aryse author Pozo Sanchez, Francisco author Pérez-Gimeno, Gloria author Castilla, Jesús author Machado, Ausenda author Džiugytė, Aušra author Karabuva, Svjetlana author Fitzgerald, Margaret author Fierens, Sébastien author Tolksdorf, Kristin author Popovici, Silvia-Odette author Mickiene, Aukse author Túri, Gergő author Součková, Lenka author Nicolay, Nathalie author Rose, Angela Mc author European Hospital Vaccine Effectiveness Group author 2024-01 We conducted a multicentre hospital-based test-negative case-control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14-89 days post-vaccination, 15% (95% CI: -12 to 35) at 90-179 days, and lower to no effect thereafter. Euro Surveill. 2024 Jan;29(3):2300708. 10.2807/1560-7917.ES.2024.29.3.2300708 1560-7917 Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 38240061 http://hdl.handle.net/20.500.12105/18998 COVID-19 COVID-19 bivalent vaccines Europe Hospitalisation SARI SARS-CoV-2 Vaccine effectiveness XBB Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023